Home »
1996 Issues »
61 FR (05/03/1996) » 96-11012. Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning A Vaccine Against Gram- Negative Bacterial Infections
96-11012. Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning A Vaccine Against Gram- Negative Bacterial Infections
[Federal Register Volume 61, Number 87 (Friday, May 3, 1996)]
[Notices]
[Page 19910]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-11012]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Application Concerning A Vaccine Against Gram-
Negative Bacterial Infections
AGENCY: U.S. Army Medical Research and Materiel Command, DOD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability for licensing of U.S. Patent Application Serial No. 08/
230,402 entitled ``Vaccine Against Gram-Negative Bacterial Infections''
and 20 April, 1994 and Foreign Patent Application PCT/US95/04446 filed
April 20, 1995. This patent has been assigned to the United States
Government as represented by the Secretary of the Army.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.
FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney,
(301) 619-2065 or telefax (301) 619-7714.
SUPPLEMENTARY INFORMATION: The invention relates to a vaccine which is
effective in inducing the production of antibodies with which to
immunize a second subject passively against infection by Gram-negative
bacteria and LPS-mediated pathology. The vaccine comprises a non-
covalent polyvalent complex formed between purified, detoxified LPS
derived from E. coli and purified outer membrane protein derived from
N. meningitidis. The same vaccine will also actively immunize a host
subject against Gram-negative bacterial infections and LPS-mediated
pathology. Meningococcal infections are included among those Gram-
negative bacterial infections protected against by the vaccine.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 96-11012 Filed 5-2-96; 8:45 am]
BILLING CODE 3710-08-M
Document Information
- Published:
- 05/03/1996
- Department:
- Army Department
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 96-11012
- Pages:
- 19910-19910 (1 pages)
- PDF File:
-
96-11012.pdf